TERAPIA INHALADA. TEORÍA Y PRÁCTICA
22. Máiz L, Lamas A, Fernández-Olmos A, Suárez L, Cantón R. Unorthodox long-term aerosolized ampicillin use for methicillin susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient. Pediatr Pulmonol. 1998; 26: 287-9. 23. Knechtel SA, Klepser ME. Safety of aerosolised amphotericin B. Expert Opin Drug Saf. 2007; 6: 523-32. 24. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994; 331: 637-42. 25. Flume PA, O´Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007; 176: 957-69. 26. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006; 354: 241-50. 27. Olschewski H, Simonneau G, Galie N, Higenbottan T, Naeije R, Rubin L, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347: 322-9. 28. Van der Wouden JC, Uijen JH, Bernsen RM, Tasche MJ, de Jongste JC, Ducharme F. Inhaled sodium cromoglycate for asthma in children. Cochrane Database Syst Rev. 2008; (4): CD002173.
- 48 -